Table 3.
Treatment choices, concomitant medication and prospective management of potential drug–drug interactions (DDIs)
| Diagnosis (n = 313) | Treatment line/choices | Concomitant medication | Potential DDIs | Risk rating and interventions (%) | Outcomes measures n (%) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1st line n (%) |
2nd line n (%) |
3rd line n (%) |
Median (IQR) | Min–max | Patients n (%) |
Grade 1, 2 | Grade 3, 5 | Failed, relapsed | Tx stopped early, LOF | SVR12* | ETR achieved | mITT % cure rate | |
| HCV (n = 154) | 151 (98.1)a | 3 (1.9) | – | 2 (1–4)b | 0–12 | 21 (13.6)c | 76.2,10.4 | 11.6,1.8d | 07 (4.5) | 2 (1.3), 1 (0.6) | 129 (83.8) | 14 (9.1) | 95.3 |
| HCV/HIV (n = 124)^ | 110 (88.7)a | 10 (8.1) | 2 (1.6) | 3 (2–5)b | 0–16 | 56 (45.2)c | 24.2,30.6 | 10.4, 12.1, 22.7 (gr. 4)d | 04 (3.2) | 2 (1.6), 7 (5.6) | 84 (67.7) | 15 (12.1) | 96.1 |
| HCV/CKD (n = 35)^ | 20 (57.1)a | 13 (37.1) | – | 8 (4–9)b | 0–13 | 19 (54.3)c | 17.1,28.6 | 28.5,25.8d | 03 (8.6) | 2 (5.7), 00 | 26 (74.3) | 02 (5.7) | 90.3 |
DDIs drug–drug interactions, SD standard deviation, MDT multidisciplinary team, SVR 12 sustained virologic response at week 12 post treatment, LOF loss of follow up, HCV hepatitis C virus, HIV human immunodeficiency virus, CKD chronic kidney disease. Gr grade, rating of DDI interventions are in accordance to validation of British Hospital Pharmacist Group (BHPG), mITT modified intention to treat analysis [representing; Tx of HCV patients was approved at MDT but not commenced and ongoing treatments awaiting 12 week SVR (3 patients in HCV/HIV, 2 patients from HCV/CKD)]
A P value < 0.05 was taken significant. All parameters with superscript a, b, c, d and * are significantly different among groups. Note: Two cases were deferred in each of HCV/HIV and HCV/CKD group as change in concomitant medication was required
^ represents comorbidities